Rijksinstituut voor Volksgezondheid en Milieu (RIVM)
Nationaal Kompas Volksgezondheid
Zoeken

Inflammatoire darmziekten

Kort en bondig

De ziekte, de determinanten en de zorg voor de patiënt

Omvang van het probleem

Geografische verschillen

Kijk ook eens bij:

.

Bronnen en Literatuur

Bronnen

Literatuur

  • Ahmad T, Marshall SE, Jewell D.Genetics of inflammatory bowel disease: the role of the HLA complex. World J Gastroenterol, 2006; 12: 3628-35.
  • Arnott ID, Ho GT, Nimmo ER, Satsangi J.Toll-like receptor 4 gene in IBD: further evidence for genetic heterogeneity in Europe. Gut, 2005; 54: 308.
  • Assche G van, Vermeire S, Rutgeerts P.Safety issues with biological therapies for inflammatory bowel disease. Current Opinion in Gastroenterology, 2006; 22: 370-6.
  • Baumgart DC, Carding SR.Inflammatory bowel disease: cause and immunobiology. Lancet, 2007; 369: 1627-40.
  • Baumgart DC, Sandborn WJ.Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet, 2007; 369: 1641-57.
  • Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J.Predictors of Crohn's disease. Gastroenterology, 2006; 130: 650-6.
  • Bernstein CN, Wajda A, Blanchard JF.The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology, 2005; 129: 827–36.
  • Biancone L, Calabrese E, Petruzziello C, Pallone F.Treatment with biologic therapies and the risk of cancer in patients with IBD. Nature Clinical Practice, 2007; 4: 78-91.
  • Bodegraven AA van, Curley CR, Hunt KA, Monsuur AJ, Linskens RK, Onnie CM, et al.Genetic variation in myosin IXB is associated with ulcerative colitis. Gastroenterology, 2006; 131: 1768-74.
  • Bodegraven AA van, Peña AS.Treatment of extraintestinal manifestations in inflammatory bowel disease. Curr Treat Options Gastroenterol, 2003; 6: 201-12.
  • Casellas F, Rodrigo L, Nino P, Pantiga C, Riestra S, Malagelada JR.Sustained improvement of health-related quality of life in Crohn's disease patients treated with infliximab and azathioprine for 4 years Inflammatory Bowel Diseases, 2007; 13(11): 1395-400.
  • Cebolla J, Lopez Zaborras J, Sopena F, Nerin JM, Gomollon F, Sainz R.The epidemiological aspects of Crohn's disease in Zaragoza. Rev Esp Enferm Dig 1991; 79: 186-189.
  • Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, et al.Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology, 2007 ; 132: 52-65.
  • Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al.Long-term evolution of disease behavior of Crohn's disease. Inflammatory Bowel Diseases, 2002; 8: 244-50.
  • D’Amato M, Bruce S, Bresso F, Zucchelli M, Ezer S, Pulkkinen V, et al.Neuropeptide S Receptor 1 Gene Polymorphism Is Associated With Susceptibility to Inflammatory Bowel Disease. Gastroenterology, 2007; 133: 808-17.
  • Danese S, Sans M, De la Motte C, Graziani C, West G, Phillips MH, et al.Angiogenesis as a novel component of inflammatory bowel disease pathogenesis. Gastroenterology, 2006; 130(7): 2060-73.
  • Darfeuille-Michaud A, Boudeau J, Bulois P, Neut C, Glasser AL, Barnich N, et al.High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn's disease. Gastroenterology, 2004; 127: 412-21.
  • Darfeuille-Michaud A, Neut C, Barnich N, Lederman E, Di Martino P, Desreumaux P, et al.Presence of adherent Escherichia coli strains in ileal mucosa of patients with Crohn's disease. Gastroenterology, 1998; 115: 1405-13.
  • Devlin SM, Yang H, Ippoliti A, Taylor KD, Landers CJ, Su X, et al.NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology, 2007; 132: 576-86.
  • Dorn SD, Sandler RS.Inflammatory bowel disease is not a risk factor for cardiovascular disease mortality: results from a systematic review and meta-analysis. The American Journal of Gastroenterology, 2007; 102: 662-7.
  • Duerr RH, Taylor KD, Brant SR, Rioux JD, Silverberg MS, Daly MJ, et al.A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science, 2006; 314: 1461-3.
  • Eliakim AR.Video capsule endoscopy of the small bowel (PillCam SB). Current Opinion in Gastroenterology, 2006; 22: 124-7.
  • Feagan BG, Reinisch W, Rutgeerts P, Sandborn WJ, Yan S, Eisenberg D, et al.The effects of infliximab therapy on health-related quality of life in ulcerative colitis patients. The American Journal of Gastroenterology, 2007; 102: 794-802.
  • Fellermann K, Stange DE, Schaeffeler E, Schmalzl H, Wehkamp J, Bevins CL, et al.A chromosome 8 gene-cluster polymorphism with low human beta-defensin 2 gene copy number predisposes to Crohn disease of the colon. American Journal of Human Genetics, 2006; 79: 439-48.
  • Fuss IJ, Heller F, Boirivant M, Leon F, Yoshida M, Fichtner-Feigl S, et al.Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. The Journal of Clinical Investigation, 2004; 113: 1490-7.
  • Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al.A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology: Vienna 1998. Inflammatory Bowel Diseases, 2000; 6: 8-15.
  • Gionchetti P, Rizzello F, Lammers KM, Morselli C, Sollazzi L, Davies S, et al.Antibiotics and probiotics in treatment of inflammatory bowel disease. World J Gastroenterol, 2006 a; 12: 3306-13.
  • Gionchetti P, Rizzello F, Lammers KM, Morselli C, Tambasco R, Campieri M.Antimicrobials in the management of inflammatory bowel disease. Digestion, 2006b; 73 (Suppl 1): 77-85.
  • Hampe J, Franke A, Rosenstiel P, Till A, Teuber M, Huse K, et al.A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nature Genetics, 2007; 39: 207-11.
  • Hampe J, Frenzel H, Mirza MM, Croucher PJ, Cuthbert A, Mascheretti S, et al.Evidence for a NOD2-independent susceptibility locus for inflammatory bowel disease on chromosome 16p. Proc Natl Acad Sci USA, 2002; 99(1): 321-6.
  • Heel DA van, Ghosh S, Butler M, Hunt KA, Lundberg AM, Ahmad T, et al.Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet, 2005; 365: 1794-6.
  • Hoeymans N, Melse JM, Schoemaker CG (red.). Gezondheid en determinanten. Deelrapport van de Volksgezondheid Toekomst Verkenning 2010 Van gezond naar beter. RIVM-rapport nr. 270061006. Bilthoven: RIVM,2010.
  • Hoie O, Wolters F, Riis L, Aamodt G, Solberg C, Bernklev T, et al.Ulcerative colitis: patient characteristics may predict 10-yr disease recurrence in a European-wide population-based cohort. The American Journal of Gastroenterology, 2007; 102: 1692-701.
  • Huerta C, Johansson S, Wallander MA, Garcia Rodriguez LA.Risk factors and short-term mortality of venous thromboembolism diagnosed in the primary care setting in the United Kingdom. Archives of Internal Medicine, 2007; 167: 935-43.
  • Hugot JP, Chamaillard M, Zouali H, Lesage S, Cezard JP, Belaiche J.Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature, 2001; 411: 599-603.
  • IBD Working Group.Inflammatory bowel disease in children and adolescents: recommendations for diagnosis - the Porto criteria. J Pediatr Gastroenterol Nutr, 2005; 41(1): 1-7.
  • Irving PM, Gearry RB, Sparrow MP, Gibson PR.Review article: appropriate use of corticosteroids in Crohn's disease. Alimentary Pharmacology & Therapeutics, 2007; 26: 313-29.
  • Jarnerot G.Infliximab or cyclosporine for severe ulcerative colitis. Gastroenterology, 2006; 130: 286.
  • Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI.Increased risk of intestinal cancer in Crohn's disease: a meta-analysis of population-based cohort studies. The American Journal of Gastroenterology, 2005; 100: 2724-9.
  • Jess T, Loftus Jr. EV, Velayos FS, Harmsen WS, Zinsmeister AR, Smyrk TC, et al.Risk of intestinal cancer in inflammatory bowel disease: a population-based study from Olmsted county, Minnesota. Gastroenterology, 2006; 130: 1039-46.
  • Karimi O, Pena AS.Probiotics: Isolated bacteria strain or mixtures of different strains? Two different approaches in the use of probiotics as therapeutics. Drugs Today (Barc), 2003; 39: 565-97.
  • Karvellas CJ, Fedorak RN, Hanson J, Wong CK.Increased risk of colorectal cancer in ulcerative colitis patients diagnosed after 40 years of age. Journal Canadien de Gastroenterologie, 2007; 21: 443-6.
  • Kastelein RA, Hunter CA, Cua DJ.Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annual Review of Immunology, 2007; 25: 221-42.
  • Koutroubakis I, Manousos ON, Meuwissen SG, Peña AS.Environmental risk factors in inflammatory bowel disease. Hepato-gastroenterology, 1996; 43: 381-93.
  • Koutroubakis IE.Therapy insight: Vascular complications in patients with inflammatory bowel disease. Nat Clin Pract Gastroenterol Hepatol, 2005; 2(6): 266-72.
  • Lakatos L, Lakatos PL.Is the incidence and prevalence of inflammatory bowel diseases increasing in Eastern Europe? Postgrad Med J, 2006; 82(967): 332-7.
  • Lakatos PL.Recent trends in the epidemiology of inflammatory bowel diseases: up or down? World J Gastroenterol, 2006; 12(38): 6102-8.
  • Langholz E, Munkholm P, Davidsen M, Binder V.Course of ulcerative colitis: analysis of changes in disease activity over years. Gastroenterology, 1994; 107: 3-11.
  • Langholz E, Munkholm P, Davidsen M, Nielsen OH, Binder V.Changes in extent of ulcerative colitis - A study on the course and prognostic factors. Scand J Gastroenterol 1996; 31: 260-266.
  • Libioulle C, Louis E, Hansoul S, Sandor C, Farnir F, Franchimont D, et al.Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet, 2007; 3(4): e58.
  • Loftus EV.Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology, 2004; 126(6): 1504-17.
  • Maartense S, Dunker MS, Slors JF, Cuesta MA, Gouma DJ, Deventer SJ van, et al.Hand-assisted laparoscopic versus open restorative proctocolectomy with ileal pouch anal anastomosis: a randomized trial. Annals of Surgery, 2004; 240: 984-91.
  • MacDonald TT, Monteleone G.Overview of the role of the immune system in the pathogenesis of inflammatory bowel disease. Advances in Experimental Medicine and Biology, 2006; 579: 98-107.
  • Mahid SS, Minor KS, Soto RE, Hornung CA, Galandiuk S.Smoking and inflammatory bowel disease: a meta-analysis. Mayo Clinic Proceedings, 2006; 81: 1462-71.
  • Marceau C, Alves A, Ouaissi M, Bouhnik Y, Valleur P, Panis Y.Laparoscopic subtotal colectomy for acute or severe colitis complicating inflammatory bowel disease: a case-matched study in 88 patients. Surgery, 2007; 141: 640-4.
  • Mate-Jimenez J, Munoz S, Vicent D, Pajares JM.Incidence and prevalence of ulcerative colitis and Crohn's disease in urban and rural areas of Spain from 1981 to 1988. J Clin Gastroenterol 1994; 18: 27-31.
  • Nerich V, Monnet E, Etienne A, Louafi S, Ramee C, Rican S, et al.Geographical variations of inflammatory bowel disease in France: a study based on national health insurance data. Inflammatory bowel diseases, 2006; 12(3): 218-26.
  • Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, et al.A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature, 2001; 411: 603-6.
  • Oresland T.Review article: colon-saving medical therapy vs. colectomy in ulcerative colitis - the case for colectomy. Alimentary Pharmacology & Therapeutics, 2006; 24, Suppl 3: 74-9.
  • Otley A, Steinhart AH.Budesonide for induction of remission in Crohn's disease. Cochrane Database of Systematic Reviews (Online), 2005: CD000296.
  • Ouaissi M, Alves A, Bouhnik Y, Valleur P, Panis Y.Three-step ileal pouch-anal anastomosis under total laparoscopic approach for acute or severe colitis complicating inflammatory bowel disease. Journal of the American College of Surgeons, 2006; 202: 637-42.
  • Papadakis KA, Yang H, Ippoliti A, Mei L, Elson CO, Hershberg RM, et al.Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflammatory Bowel Diseases, 2007; 13: 524-30.
  • Parkes M, Barrett JC, Prescott NJ, Tremelling M, Anderson CA, Fisher SA, et al.Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. Nature Genetics, 2007; 39: 830-2.
  • Peltekova VD, Wintle RF, Rubin LA, Amos CI, Huang Q, Gu X, et al.Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nature Genetics, 2004; 36: 471-5.
  • Perez-Cuadrado E, Mas P, Hallal H, Shanabo J, Munoz E, Ortega I, et al.Double-balloon enteroscopy: a descriptive study of 50 explorations. Rev Esp Enferm Dig, 2006; 98: 73-81.
  • Polle SW, Bemelman WA.Surgery insight: minimally invasive surgery for IBD. Nature Clinical Practice, 2007; 4: 324-35.
  • Poos MJJC, Smit JM, Groen J, Kommer GJ, Slobbe LCJ. Kosten van ziekten in Nederland 2005. RIVM-rapport nr. 270751019. Bilthoven: RIVM,2008.
  • Prescott NJ, Fisher SA, Franke A, Hampe J, Onnie CM, Soars D, et al.A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn's disease and is independent of CARD15 and IBD5. Gastroenterology, 2007; 132: 1665-71.
  • Regueiro M, Curtis J, Plevy S.Infliximab for hospitalized patients with severe ulcerative colitis. Journal of Clinical Gastroenterology, 2006; 40: 476-81.
  • Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al.Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nature Genetics, 2007; 39: 596-604.
  • Roos JC, Ostor AJ.Neurological complications of infliximab. The Journal of Rheumatology, 2007; 34: 236-7.
  • Russel MGVM, Dorant E, Volovics A, et al.High incidence of inflammatory bowel disease in The Netherlands: results of a prospective study. Dis Colon Rectum 1998; 41 (1): 33-40.
  • Russel MGVM, Kruijs M van de, Engels L, Muris J, Wijlick E van, Stockbrugger RW.South Limburg IBD Study Group. Maastricht: Academisch Ziekenhuis Maastricht, 1995.
  • Rutgeerts P, Assche G van, Vermeire S.Review article: Infliximab therapy for inflammatory bowel disease--seven years on. Alimentary Pharmacology & Therapeutics, 2006b; 23: 451-63.
  • Rutgeerts P, Diamond RH, Bala M, Olson A, Lichtenstein GR, Bao W, et al.Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointestinal Endoscopy, 2006a; 63: 433-42.
  • Rutter MD, Saunders BP, Wilkinson KH, Rumbles S, Schofield G, Kamm MA, et al.Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology, 2006; 130: 1030-8.
  • Sandborn WJ, Kamm MA, Lichtenstein GR, Lyne A, Butler T, Joseph RE.MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alimentary Pharmacology & Therapeutics, 2007; 26: 205-15.
  • Sandborn WJ, Lofberg R, Feagan BG, Hanauer SB, Campieri M, Greenberg GR.Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials. The American Journal of Gastroenterology, 2005; 100: 1780-7.
  • Satsangi J, Silverberg MS, Vermeire S, Colombel JF.The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut, 2006; 55: 749-53.
  • Scala J.The New Eating Right for a Bad Gut: The Complete Nutritional Guide to Ileitis, Colitis, Crohn's Disease, and Inflammatory Bowel Disease. New York: Plume, 2000.
  • Schreiber S, Khaliq-Kareemi M, Lawrance IC, Thomsen OO, Hanauer SB, McColm J, et al.Maintenance therapy with certolizumab pegol for Crohn's disease. The New England Journal of Medicine, 2007; 357: 239-50.
  • Schwab M, Schaeffeler E, Marx C, Fromm MF, Kaskas B, Metzler J, et al.Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis. Gastroenterology, 2003; 124: 26-33.
  • Shivananda S, Lennard-Jones JE, Logan R, Fear N, Price A, Carpenter L, et al.Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European collaborative study on inflammatory bowel disease (EC-IBD). Gut, 1996; 39: 690-7.
  • Shivananda S, Peña AS, Mayberry JF, Ruitenberg EJ, Hoedemaeker PhJ.Epidemiology of proctocolitis in the regio Leiden, the Netherlands. A population study from 1979 to 1983. Scand J Gasteroenterol 1987a; 22: 993-1002.
  • Shivananda S, Peña AS, Nap M, Weterman IT, Mayberry JF, Ruitenberg EJ, Hoedemaeker PhJ.Epidemiology of Crohn's disease in regio Leiden, the Netherlands. A population study from 1979 to 1983. Gastroenterol 1987b; 93: 966-974.
  • Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al.Toward an integrated clinical, molecular, and serological classification of inflammatory bowel disease. Journal Canadien de Gastroenterologie, 2005; 19, suppl. A: 5-36.
  • Sonnenberg A.Time trends of mortality from Crohn's disease and ulcerative colitis. Int J Epidemiol, 2007a; 36(4): 890-9.
  • Sonnenberg A.Similar geographic variations in mortality from peptic ulcer and inflammatory bowel disease. Inflamm Bowel Dis, 2007b; 13(6): 763-8.
  • Stoll M, Corneliussen B, Costello CM, Waetzig GH, Mellgard B, Koch WA, et al.Genetic variation in DLG5 is associated with inflammatory bowel disease. Nature Genetics, 2004; 36: 476-80.
  • Torok HP, Glas J, Tonenchi L, Lohse P, Muller-Myhsok B, Limbersky O, et al.Polymorphisms in the DLG5 and OCTN cation transporter genes in Crohn's disease. Gut, 2005; 54: 1421-7.
  • Trallori G, d'Albasio G, Palli D, et al.Epidemiology of inflammatory bowel disease over a 10-year period in Florence (1978-1987). Ital J Gastroenterol 1991; 23: 559-563.
  • Velayos FS, Terdiman JP, Walsh JM.Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. The American Journal of Gastroenterology, 2005; 100: 1345-53.
  • Veloso FT, Carvalho J, Magro F.Immune-related systemic manifestations of inflammatory bowel disease. A prospective study of 792 patients. Journal of Clinical Gastroenterology, 1996; 23: 29-34.
  • Wehkamp J, Harder J, Weichenthal M, Schwab M, Schaffeler E, Schlee M, et al.NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression. Gut, 2004; 53: 1658-64.
  • Wellcome Trust Case Control Consortium.Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature, 2007; 447: 661-78.
  • Winther KV, Jess T, Langholz E, Munkholm P, Binder V.Long-term risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen County. Clin Gastroenterol Hepatol, 2004; 2: 1088-95.
  • Wolfe F, Michaud K.The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis and Rheumatism, 2007; 56: 1433-9.
  • Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al.Crohn's disease: increased mortality 10 years after diagnosis in a Europe-wide population based cohort. Gut, 2006; 55: 510-8.
  • Wolters FL, Russel MG, Sijbrandij J, Schouten LJ, Odes S, Riis L, et al.Disease outcome of inflammatory bowel disease patients: general outline of a Europe-wide population-based 10-year clinical follow-up study. Scand J Gastroenterol Suppl, 2006; 243(5): 46-54.
  • Wolters FL, Russel MG, Stockbrugger RW.Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Alimentary Pharmacology & Therapeutics, 2004; 20: 483-96.
  • Xavier RJ, Podolsky DK.Unravelling the pathogenesis of inflammatory bowel disease. Nature, 2007; 448: 427-34.

Begrippen en afkortingen

Afkortingen

CT
Computer tomography
Röntgentechniek waarbij een computerprogramma meerdere afbeeldingen van het lichaam combineert tot dwarsdoorsneden of driedimensionale beelden van organen/weefsels.
ICD
International Classification of Diseases
Internationale classificatie van ziekten.
ICPC
International classification of primary care
MRI
Magnetic resonance imaging
Magnetische Resonantie Computer Tomografie. Een onschadelijke beeldvormende techniek waarmee dwarsdoorsneden van het lichaam kunnen worden gemaakt. Het maakt gebruik van de eigenschap van atoomkernen om onder invloed van radiogolven zelf energie uit te gaan stralen.

Definities

Anamnese
Wat een patiënt de arts over de klachten en medische voorgeschiedenis kan vertellen.
Differentiële diagnose
Het stellen van een diagnose door het afwegen van de waargenomen verschijnselen tegen die van verschillende bekende ziektebeelden.
Immuniteit
De bescherming tegen infectieziekten door aanwezigheid van antistoffen en/of gerichte activiteit van witte bloedcellen.Immuniteit kan passief of actief verkregen zijn; passief via de placenta in de zwangerschap of door toedienen van gammaglobuline, zoals bij verwondingen of bloedtransfusies; actieve immuniteit kan verkregen worden bij het doormaken van ziektes of door vaccinaties.
Primaire doodsoorzaak
De ziekte of de gebeurtenis waarmee de aaneenschakeling van gebeurtenissen die tot de dood leidde, startte. Men spreekt hierbij wel van de onderliggende ziekte of het grondlijden (Bron: CBS).
Recidief
Het opnieuw optreden van de (verschijnselen van de) ziekte.
Remissie
Tijdelijke of blijvende vermindering of verdwijning van ziekteverschijnselen.
Volksgezondheid Toekomst Verkenning, Nationaal Kompas Volksgezondheid. Bilthoven: RIVM, <http://www.nationaalkompas.nl> versie 4.7, 22 maart 2012